dc.contributor.author | Munafò, Antonio | |
dc.contributor.author | Arillotta, Davide | |
dc.contributor.author | Mannaioni, Guido | |
dc.contributor.author | Schifano, Fabrizio | |
dc.contributor.author | Bernardini, Renato | |
dc.contributor.author | Cantarella, Giuseppina | |
dc.contributor.editor | Espuny, Antoni Camins | |
dc.date.accessioned | 2023-01-25T12:45:01Z | |
dc.date.available | 2023-01-25T12:45:01Z | |
dc.date.issued | 2022-12-31 | |
dc.identifier.citation | Munafò , A , Arillotta , D , Mannaioni , G , Schifano , F , Bernardini , R , Cantarella , G & Espuny , A C (ed.) 2022 , ' Psilocybin for Depression: From Credibility to Feasibility, What’s Missing? ' , Pharmaceuticals , vol. 16 , no. 1 , 68 , pp. 1-11 . https://doi.org/10.3390/ph16010068 | |
dc.identifier.issn | 1424-8247 | |
dc.identifier.other | Jisc: 860058 | |
dc.identifier.other | Jisc: 860058 | |
dc.identifier.other | publisher-id: pharmaceuticals-16-00068 | |
dc.identifier.uri | http://hdl.handle.net/2299/26023 | |
dc.description | © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). | |
dc.description.abstract | Psilocybin has been suggested as a promising transdiagnostic treatment strategy for a wide range of psychiatric disorders. Recent findings showed that psychedelic-assisted/”psycholitic” psychotherapy should provide significant and sustained alleviation of depressive symptoms. However, to date, there have been several study limitations (e.g., small sample sizes, blinding, limited follow-up, highly screened treatment populations) and some health/political issues, including practitioners’ experience, lack of standardized protocols, psychedelics’ legal status, ethical concerns, and potential psychological/psychopathological/medical untoward effects. The focus here is on a range of clinical and methodological issues, also aiming at outlining some possible suggestions. We are confident that newer evidence, more precise protocols, and eventual reclassification policies may allow a better understanding of the real potential of psilocybin as a transdiagnostic therapeutic molecule. | en |
dc.format.extent | 11 | |
dc.format.extent | 319847 | |
dc.language.iso | eng | |
dc.relation.ispartof | Pharmaceuticals | |
dc.subject | Opinion | |
dc.subject | psilocybin | |
dc.subject | depression | |
dc.subject | clinical trials | |
dc.subject | methodological issues | |
dc.subject | ethical concerns | |
dc.title | Psilocybin for Depression: From Credibility to Feasibility, What’s Missing? | en |
dc.contributor.institution | Department of Clinical, Pharmaceutical and Biological Science | |
dc.contributor.institution | Centre for Health Services and Clinical Research | |
dc.contributor.institution | Psychopharmacology, Drug Misuse and Novel Psychoactive Substances Unit | |
dc.contributor.institution | School of Life and Medical Sciences | |
dc.description.status | Peer reviewed | |
rioxxterms.versionofrecord | 10.3390/ph16010068 | |
rioxxterms.type | Journal Article/Review | |
herts.preservation.rarelyaccessed | true | |